Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03773302
Recruitment Status : Recruiting
First Posted : December 12, 2018
Last Update Posted : April 27, 2022
Helsinn Healthcare SA
Information provided by (Responsible Party):
QED Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 30, 2026
Estimated Study Completion Date : December 30, 2026